A detailed history of Raymond James Financial Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 102,061 shares of KRYS stock, worth $16.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
102,061
Holding current value
$16.6 Million
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025

BUY
$156.64 - $199.61 $16 Million - $20.4 Million
102,061 New
102,061 $16 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.17B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.